Conazoles are fungicides used to control fungal growth in environmental settings and to treat humans with fungal infections. Mouse hepatotumorigenic conazoles display many of the same hepatic toxicologic responses as the mouse liver carcinogen phenobarbital (PB): constitutive androstane receptor (CAR) activation, hypertrophy, Cyp2b induction, and increased cell proliferation. The goal of this study was to apply transcriptional analyses to hepatic tissues from mice exposed to PB, propiconazole (Pro) or triadimefon (Tri) at tumorigenic exposure levels to reveal similarities and differences in response among these treatments. Mice were administered diets containing PB (850 ppm), Pro (2500 ppm), or Tri (1800 ppm) for 4 and 30 days. Targeted transcriptomic analyses were conducted at the gene level examining differentially expressed genes (DEGs), and subsets of DEGs: cell cycle genes, and transcription factors. Analyses were also conducted on function, pathway and network levels examining Ingenuity Pathway Analysis Tox Lists and Canonical Pathways, and Gene-Go MetaCore dynamic networks and their central hubs. Genes expressed by PB or the two conazoles were also compared with those genes associated with human hepatocellular cancer. The results from these analyses indicated greater differences between PB and the two conazoles than similarities. Significant commonalities between the two conazole treatments were also noted. We posit that the transcriptional profiles of tissues exposed to toxic chemicals inherently contain their mechanisms of toxicity. We conclude that although PB and these 2 conazoles induce mouse liver tumors and exhibit similar toxicological responses, their transcriptional profiles are significantly different and thus their mechanisms of tumorigenic action are likely to differ.
Conazoles are fungicides used to control fungal growth on fruits, vegetables, grasses, seeds, and used for foliar disease prevention (Zarn et al., 2003) . Pharmaceutical conazoles are used for the treatment of local and systemic fungal infections (Georgopapadakou and Walsh, 1996) . Some members of this class of fungicide have adverse toxicological outcomes in rodents as they have been found to be carcinogens, reproductive toxins, and hepatotoxins (INCHEM, 1981 (INCHEM, , 1987 (INCHEM, , 1992 (INCHEM, , 1997 (INCHEM, , 2001 Juberg et al., 2006; Peffer et al., 2007) . Conazoles were designed to inhibit a specific cytochrome P450 (CYP), CYP51 (lanosterol-14-a-demethylase), a critical step in the biosynthesis of ergosterol, a steroid required for the formation of the fungal cell wall (Zarn et al., 2003) . In mammalian systems many conazoles both induce and inhibit hepatic CYPs. In mice, a number of conazoles have been reported to induce several hepatic CYP isoforms with Cyp2b10/20, Cyp3a11, and Cyp3a13 being the most common forms Juberg et al., 2006; Peffer et al., 2007; Sun et al., 2005 Sun et al., , 2006 . The induction of these CYPs is mediated through the activation of the nuclear receptors, the constitutive androstane receptor (CAR) and the pregnane X receptor (PXR) (Maglich et al., 2002; Nallani et al., 2003) . Many of these conazoles induce hepatomegaly and increase hepatic cell proliferation in mice Juberg et al., 2006; Peffer et al., 2007) . The mechanism(s) of action of these structurally similar compounds that result in hepatotumorigenesis remains unclear and has been the subject of current investigations Chen et al., 2008 Chen et al., , 2009 Juberg et al., 2006; Peffer et al., 2007; Ross et al., 2008; Sun et al., 2006 Sun et al., , 2007 Ward et al., 2006) .
Phenobarbital (PB) is a prototypical mouse liver tumorigen and it has been proposed that PB induces tumors by a mechanism involving liver hyperplasia . Genotoxicity evaluations of PB are generally negative and it is considered to be a nongenotoxic carcinogen (IARC, 2001) . PB activates CAR and induces Cyp2b protein by a mechanism that includes AMP-activated protein kinase (Shindo et al., 2007) . CAR knockout mice initiated with diethylnitrosamine and promoted with PB were refractory to liver cancer suggesting that CAR plays a role in PB mouse liver promotion (Yamamoto et al., 2004) . PB is also associated with hepatic responses related to its tumorigenic effects: hypertrophy, increased cell proliferation, and inhibition of apoptosis (IARC, 2001 ). There are extensive epidemiologic studies on patients who have been on long-term PB therapy showing no increase in the incidence of hepatic cancer, even though their PB plasma levels were close to those found in susceptible rodents (IARC, 2001) . For that reason, chemicals that are mouse liver tumorigens and produce PB-associated responses in mouse liver are considered to be ''PB-like'' and their tumorigenic responses have been deemed not relevant to humans (Holsapple et al., 2006) . This analysis was based on a mode of action (MOA) framework using the general principles involved in the chemical induction of a specific tumor in animals (Sonich-Mullin et al., 2001 ). The assumption is that these toxicological responses (CAR activation, hypertrophy, Cyp2b induction, increased cell proliferation, and inhibition of apoptosis) define the MOA of PB and therefore chemicals that display these characteristics are ''PB-like'' and their tumorigenic effects in rodents are not relevant to the evaluation of their ability to induce human cancer.
Propiconazole (Pro) and triadimefon (Tri) are two mouse hepatotumorigenic conazoles that display many of the same hepatic toxicological responses as PB: CAR activation, hypertrophy, Cyp2b induction, and increased cell proliferation (INCHEM, 1981 (INCHEM, , 1987 Allen et al., 2006) and decreases in apoptosis (data not shown). In this study we applied transcriptomic analyses to liver tissues from mice exposed to PB, Pro, or Tri at tumorigenic doses levels to probe more deeply into, and characterize, the similarities and differences between PB and those two mouse tumorigenic conazoles. The results of this study provide a more scientifically defensible approach to determining whether the mechanism of tumorigenesis of these pesticides are unlike PB, or like PB, and thus potentially relevant or not relevant to humans. Moreover, these data may be informative for the assessment of human relevance.
MATERIALS AND METHODS
Chemicals. PB, sodium was obtained from Sigma Chemical Co. (St Louis, MO) . The source and purity of each conazole has been reported in Allen et al. (2006) .
Conazole studies. The complete details of the in-life experiments for Pro and Tri were described in Allen et al. (2006) . Briefly, male CD-1 mice received Pro (2500 ppm) or Tri (1800 ppm) in the feed or, control feed for periods of 4 and 30 days. This resulted in an average daily intake of 349.6 ± 46.7 of Pro and 257.1 ± 33.5 mg/kg/day of Tri. The procedures for mRNA isolation, purification and analysis from liver samples have been reported previously (Ward et al., 2006) . Sample preparation, processing and hybridization to the Affymetrix mouse 430_2 arrays were performed at Expression Analysis (Durham, NC) as described in the GeneChip Expression Analysis Manual (Affymetrix, Santa Clara, CA).
Preparation of PB-treated feed. PB, sodium was admixed with powdered LabDiet SP 76 Irradiated using a Hobart mixer. The milled feed was obtained from Granville Milling Co. (Creedmoor, NC). The mixed feed was stored at four EC in plastic containers until use. Duplicate samples (100 g) of treated feed from different locations within the container were used for chemical analysis. Samples were extracted with acetonitrile/water (1/1), and aliquots of supernatant were filtered. Quantitative analyses of the levels of PB in the treated feeds were accomplished by high-performance liquid chromatography (HPLC) using an external standard curve. The target concentrations and measured mean concentrations of PB were determined over the 30-day period. The target concentration was 850 ppm and the mean measured concentration was 832 ppm ± 8.5, within 2% of the target concentration (data not shown).
Animal treatments and necropsy-PB study. Male CD-1 mice (6-8 weeks) were obtained from Charles River Laboratories (Raleigh, NC) and acclimated for 7 days in the animal facility prior to commencing exposure for 4 or 30 days. Mice were ear-tagged with unique identifying numbers and randomly assigned and housed two per polycarbonate cage with Alpha-Dry bedding in a room under a 12:12-h light:dark cycle, with controlled temperature (22°C) and humidity (45%). Water and feed were provided ad libitum. Animals were monitored daily and cages and bedding were changed twice a week. Containers of feed were weighed at regular intervals to determine feed and thereby chemical consumption. Mice were individually weighed at the start of the experiment and regularly thereafter. Control groups were fed the control rodent diet. PB-treated mice consumed an average daily intake of 97.2 ± 5.9 mg PB/ kg/day. At the end of each treatment period the animals were euthanized by CO 2 asphyxiation. After livers were removed from mice, they were weighed and either placed in 10% neutral buffered formalin or immediately snap frozen in liquid nitrogen. All animals were housed in an Association for Assessment and Accreditation of Laboratory Animal Care, International accredited US Environmental Protection Agency animal facility, and all procedures involving the use of animals were approved by the Institutional Animal Care and Use Committee.
Histopathological examination-PB study. For liver histopathology analyses, a section of liver from each mouse was taken for fixation in 10% neutral buffered formalin and processed by routine methods to 5-lm paraffin sections, stained with hematoxylin and eosin, and analyzed with light microscopy. Liver alterations were scored based on the severity of hepatocyte hypertrophy, which was the only alteration present in the majority of samples. However, a few slides did exhibit hepatocyte vacuolation in addition to the hypertrophy. The lesion scoring was based on the following criteria: 0-no lesion present, 1-centrilobular hypertrophy, 2-centrilobular and midzonal hypertrophy, 3-panlobular hypertrophy, 4-panlobular hypertrophy with cytoplasmic vacuolation.
Cell proliferation-PB study. Cell proliferation by Ki67 immunohistochemical staining was determined in livers from 4-and 30-day-treated mice by Experimental Pathology Laboratories, Inc., Durham, NC. Tissue samples in paraffin blocks were sectioned, deparaffinized, and hydrated. Samples were incubated in 1:20 citrate buffer for 7 min under pressure (decloaking) and then cooled. Blocking steps included quenching of endogenous peroxides with 3% H 2 O 2 , an avidin block, a biotin block and incubation with blocking serum. Sections were labeled with rat anti-mouse Ki67 antibody (1:25 dilution) and a rabbit anti-rat IgG secondary antibody (1:300). Slides were developed using an avidin-biotin complex method following an application of 3,3#-diaminobenzidine as the chromogen (Muskhelishvili et al., 2003) . The % labeling indices (LI) were determined by counting the number of positively stained Ki67 nuclei in 900-1400 hepatocyte nuclei/animal from photographic images taken at 403. Each image was scored and analyzed for accuracy.
RNA isolation-PB study. The frozen mouse liver tissues were ground in Tri Reagent (Molecular Research Center, Cincinnati, OH) with an IKA UltraTurrax T 25 basic tissue grinder (IKA Works, Wilmington, NC). The total RNA pellet was resuspended in 100 ll of water and purified by an RNeasy kit TRANSCRIPTIONAL COMPARISON OF PHENOBARBITAL AND CONAZOLES 69 from Qiagen (Valencia, CA). Purified total RNA was eluted in water and its concentration was measured by a NanoDrop ND-1000 spectrometer (NanoDrop, Wilmington, DE). The quality of RNA was assessed by an Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA).
Affymetrix microarray hybridization-PB study. Gene expression analysis was conducted using Affymetrix Mouse Genome 430_2.0 GeneChip arrays (Affymetrix, Santa Clara, CA). This whole mouse genome array interrogates 34,000 variants and 39,000 transcripts from well-characterized mouse genes using 45,000 probe sets. Total RNA (4 lg) for each sample was amplified and labeled by the Enzo BioArray RNA Amplification and Biotin labeling System (Enzo Life Sciences, Farmingdale, NY). For each array, 15 lg of amplified biotin-cRNAs were fragmented and hybridized to the array for 16 h at 45°C in a rotating hybridization oven using the Affymetrix eukaryotic target hybridization controls and protocol. Hybridized probe sets on the array were stained with streptavidin/phycoerythrin using a double-antibody staining procedure and washed using the EukGE-WS2v5 protocol of the Affymetrix fluidics station FS450 for antibody amplification. Arrays were scanned with an Affymetrix scanner 3000.
Microarray data analysis. The raw signal intensities from each scan (.cel files) were imported into the gene expression analysis software Rosetta Resolver version 7.1 (Rosetta Inpharmatics, Kirkland, WA). This software was used to determine which probe sets in a treatment group differed from the control group. The scans were converted into profiles within this software and the data were normalized using Rosetta error model (Weng et al., 2006) .
The conazole study was conducted in 2005 as reported in Ward et al. (2006) . The current PB study was conducted in essentially the same manner with respect to in-life procedures, mRNA isolation, and hybridization. Because the two studies were temporally separated, had different group sizes, and were hybridized in different laboratories using Affymetrix protocols, the control groups from each study were statistically compared (based on error-weighted sequence intensities) at each time point using a Pearson product-moment correlation test. The results showed that the average Pearson product-moment correlation coefficients for PB controls and conazole controls at 4 and 30 days were r 2 ¼ 0.97875, and r 2 ¼ 0.9666, respectively. This supported the comparisons between the two studies.
Statistically filtered sequences were identified using one-way ANOVA with a false discovery rate (Benjamini-Hochberg test) of p 0.05 followed by a post hoc test (Tukey-Kramer) for significance. Fold change for each sequence was computed for each calculated ratio, representative of a given sequence. The fold change expresses a decrease or an increase in a sequence's transcript abundance in treatment conditions versus the relevant control condition. Statistical lists were used in VENN diagrams to find sequences common and unique for each treatment. Using Ingenuity Pathways Analysis (IPA) (Ingenuity Systems, www.ingenuity.com), these common and unique significant transcripts were evaluated for relevance to IPA Canonical Pathways and IPA Tox Lists. The ''Compare Experiments'' function within GeneGo MetaCore (http://portal. genego.com/cgi/index.cgi#Information) was used to create significant networks from DEGs obtained from VENN analyses. The p values for MetaCore processes were calculated using a hypergeometric distribution. We considered significance at p 0.05.
Cell cycle gene database. A series of genes have been identified whose expression varies periodically over the cell cycle based on associating groups of genes with the phases of the cell cycle using hierarchical clustering from HeLa cervical cancer cell studies (Whitfield et al., 2002) . The complete list of 1134 human genes was downloaded from http://genome-www.stanford.edu/HumanCellCycle/Hela/data.shtml. The list was reduced to 709 unique gene symbols after removing unannotated, poorly annotated and duplicate genes. These gene symbols were mapped to 873 mouse 430_2.0 array probe sets using the Affymetrix annotation file, mouse430_2.na26.anot.csv.zip, downloaded from http://www.affymetrix.com/support/technical/annotationfilesmain. This resulted in 341 mouse orthologous genes found in Supplemental Table S1 .
Transcription factor analysis. Analyses were performed using the Gene Set Comparison kit module within BRB-ArrayTools, Biometric Research Branch (BRB) Array Tools Version 3.6.1 (http://linus.nci.nih.gov/BRBArrayTools.html). A detailed description of the method has been previously reported (Xu et al., 2008) . Briefly, treated and control groups were used in the Gene Set Comparison tool for transcription factor analysis. For gene sets of transcription factor targets, all genes in each gene set are either predicted or experimentally verified to be targets of the same transcription factor. The predicted targets were obtained using the web-based software Match (version 10.0, available at http://www.gene-regulation.com/pub/programs.html#match) to search the upstream sequences of genes (~1500 bp). The sequences were obtained from the Ensemble Sanger (version 40) database (available at http:// www.ensembl.org/Mus_musculus/Info/Index). The search utilized transcription factor binding weight matrices obtained from the Transfac (version 9.2, available at http://www.gene-regulation.com/pub/programs.html#match) database and the Match cut-offs to minimize the number of false positive targets. With this approach, each set contains genes that are predicted to be potential targets of the same transcription factor. Also included are separate sets of genes that have been experimentally verified as targets of the same transcription factor. We used curated transcription factor binding data from the Transcriptional Regulatory Element Database to eliminate targets without any experimental verification. The output of the analysis was statistically significant gene sets of transcription factor targets associated with one phenotype versus another. The numbers of unique genes from these gene sets were totaled.
Human hepatocellular carcinoma-associated gene database. A catalog of genes associated with human hepatocellular carcinoma (HCC) were compiled from four investigations reported in the literature (Fang et al., 2005; Ge et al., 2005; Paradis et al., 2003; Xu et al., 2001) . There were 38 genes reported by Fang et al. (2005) , 39 genes reported by Ge et al. (2005) , 42 genes reported by Paradis et al. (2003) , and 66 genes reported by Xu et al. (2001) . The lists were combined, the duplicates removed, the remaining genes converted to Entrez Gene identifiers using Rosetta Resolver and then mapped to mouse orthologs. This gave a catalog of 161 genes (Supplemental Table S2 ).
RESULTS

Effects of PB and Conazoles on Mouse Liver Weight, Histology, and Cell Proliferation
Mice were treated with PB (850 ppm), Pro (2500 ppm), or Tri (1800 ppm), exposure levels that had been reported to increase the incidence of mouse hepatocellular tumors under chronic exposure conditions (IARC, 2001; INCHEM, 1981 INCHEM, , 1987 . After 4 or 30 days of exposure the mice exhibited enlarged livers as evidenced by the highly statistically significant increases in mean liver weight, and liver to body weight changes (Table 1) . After 4 days of treatment the ratios of the treated mice to control mice for liver to body weight changes were 1.26, 1.31, and 1.17 for PB, Pro, and Tri, respectively. Histological analyses of the livers examined from all of the treated mice showed hepatocyte hypertrophy, whereas none was observed in control mice. Similarly, at 30 days all treatment groups showed hepatocyte hypertrophy with ratios of the treated to control mice for liver to body weight changes of 1.25, 1.96, and 1.6 for PB, Pro, and Tri, respectively. Cell proliferative responses in hepatic tissues from mice treated with Pro and Tri had been previously determined immunohistochemically using a proliferating cell nuclear antigen (PCNA) antibody and are presented in Table 1 . Cell proliferation in hepatic tissues from mice treated with PB was 70 NESNOW ET AL. determined by immunohistochemical methods using a Ki67 antibody. Treatment with PB and Pro for 4-day induced 13.5-and 8.9-fold increases, respectively. Tri treatment did not induce a statistically significant increase. At 30 days of treatment, Tri increased cell proliferation 10-fold, whereas PB treatment had no effect and Pro treatment did not induce a statistically significant increase. These results are comparable to effects reported in other studies where hepatic cell proliferation induced by PB decreased over time (Juberg et al., 2006; Peffer et al., 2007; Smith et al., 1991) .
Comparison of the Effects of PB with Conazoles at 4 Days of Treatment
Groups of DEGs were generated from Rosetta Resolver statistical analyses and then combined with Venn approaches for further analysis (Table 2) . PB treatment produced the greatest number of DEGs (1814) compared with treatments of mice with Pro (1021) or Tri (605). Venn analysis indicated that there were 249 genes common to PB and Pro or Tri, 1565 genes unique to PB treatment, 386 genes common to Pro and Tri treatments, 394 genes unique to Pro treatment and 61 genes unique to Tri treatment. These lists of genes were analyzed by IPA and groups of genes were mapped to IPA Tox Lists (a library of pathways based on sets of genes that are known to be perturbed upon compound treatment and eventually result in a measurable pathology), and IPA Canonical Pathways (Table 3 ). The analysis identified a group of 63 Tox Lists and or Canonical Pathways statistically significantly altered by one or more treatments with 26 of these common to both PB and conazole treatments. These included a series of lists and or pathways involving nuclear receptor activation including CAR/ PXR, peroxisome proliferative activated receptor-a (PPAR-a)/ retinoid X receptor (RXR), PXR/RXR activation; fatty acid, amino acid, and xenobiotic metabolism activities; and oxidative stress pathways. Genes unique to PB treatment mapped to a series of signaling pathways including extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK), Estrogen receptor, and Sonic Hedgehog signaling. Genes common to Pro and Tri treatments mapped to liver X receptor (LXR)/RXR and thyroid hormone receptor (TR)/RXR activation pathways, and cholesterol biosynthesis among others, that were not observed in the common or PB groups. There were 15 lists and or pathways that were unique to Pro treatment. The signaling pathways included epidermal growth factor (EGF), glucocorticoid, phosphatidylinositol 3-kinase (PI3K)/serine/threonine-specific protein kinase (AKT), and phosphatase and tensin homolog (PTEN) pathways among others, as well as a series of metabolic pathways. Genes unique to Tri mapped to farnesoid X receptor (FXR)/RXR activation pathways and to metabolic pathways not observed in the other treatment groups (i.e., androgen and estrogen metabolism and biosynthesis of steroids). These pathway analyses based on 4 days treatment data indicated commonalities between PB, Pro, and Tri treatments in metabolic pathways or lists and significant differences between PB and conazole treatments particularly in signaling pathways as well as many common pathways altered by both conazoles. GeneGo MetaCore networks were constructed using the ''Compare Experiment'' function in GeneGo MetaCore as an adjunct to the IPA fixed pathway mapping approach (Ekins et al., 2005) . Each analysis gave a series of ranked (based on the number of target genes, the numbers of Gene-Go pathways the genes populate, the p value and the Z score) networks and several of the top scored networks (first top network) are presented. The first top scored networks are found in Figures 1 and 2 from genes unique to PB treatment, and from genes altered by Pro treatment (excluding those common to three treatments) taken from Table 2 . In these networks genes are organized by the functional location of the gene products, that is, whether within or outside of the cell. Figure 1 describes the first top network from genes unique to PB treatment. The thick cyan lines represent fragments of canonical pathways that dominate this network. The network represents gene ontology (GO) processes of Ras protein signal transduction, cell motion, signal transduction, and cell communication among others. Figure 2 depicts the first top network from genes altered by Pro treatment (excluding those common to three treatments). This network is dominated by the transcription factor, hepatic nuclear factor 4a (Hnf4a). The GO processes represented within this network are signal peptide processing, signal recognition particle-dependent cotranslational protein targeting to membrane, and protein targeting to ER among others. The figure representing the first top network from genes altered by Tri treatment (excluding those common to three treatments) is found in the Supplemental Figures. Its network is similar to that produced from the Pro treatment genes and represents GO processes of cotranslational protein targeting to membrane, macromolecular localization and protein targeting. Inspection of Table 2 . Genes marked with red circles are overexpressed, whereas those marked with blue circles are underexpressed. Lines between genes indicate relationships between the two genes. The thick cyan lines indicate fragments of canonical pathways. The different symbols represent proteins, enzymes, growth factors, or other cellular components. (For the legend see Ekins et al., 2005.) TRANSCRIPTIONAL COMPARISON OF PHENOBARBITAL AND CONAZOLES these dynamic networks clearly indicates substantial differences between the conazole and PB treatments and commonalities between the two conazoles.
Each network analysis that was created for each condition produced three networks and only the first top scored network from the series is shown or described. Within each network there are genes that function as central controlling hubs connected to other genes through links or spokes which are direct interactions. We operationally defined these hubs as a gene that is associated directly with 5 other genes. By identifying these central hubs we could compare complex networks of many genes in a simpler manner across treatments. The hubs derived from the top three networks generated from genes common to all three treatments, from genes unique to PB treatment and from genes altered by Pro or Tri treatments (not including those common to all three treatments) are presented in Table 4 . Although the hubs from networks of genes common to all three treatments and from networks of genes unique to PB treatment were different, the hubs from the Pro and Tri networks were the same and included Hnf4a, Myc, and Esr1 genes.
Cell Cycle Genes (4 Days)
The significant DEGs after 4 days of treatment from Table 2 were mapped to cell cycle genes derived from the report of Whitfield et al. (2002) based on a series of genes identified with the phases of the cell cycle using hierarchical clustering from HeLa cervical cancer cell studies. The results are presented in Figure 3 organized by treatment and phases of the cell cycle. PB treatment induced expression changes in 45 genes, with the greatest number being those acting in the G2/M phase of the cell cycle. Pro treatment produced expression changes in 33 genes, whereas Tri treatment produced expression changes in 18 genes. There were six genes whose expression levels were altered by all three treatments and 11 genes with expression levels altered by Pro and Tri treatments, but not altered by PB treatment.
Comparison of the Effects of PB with Conazoles at 30 Days of Treatment
Compared with the 4 days of treatment, the number of DEGs were reduced by PB treatment but increased by conazole treatment at 30 days (Table 2) . Pro treatment produced the greatest number of DEGs (1410) compared with treatments of mice with PB (1268) or Tri (1081). Venn analysis indicated that there were 342 genes common to PB and Pro or Tri treatment, 926 genes unique to PB treatment, 571 genes common to Pro and Tri treatment, 518 genes unique to Pro treatment, and 272 genes unique to Tri treatment. As with the 4-days data, these gene lists were analyzed by IPA and groups of genes were mapped to a total of 92 IPA Tox Lists and IPA Canonical Pathways (Table 5) . Most of the pathways in the Tox Lists/Canonical Pathways that were common to both PB and conazole treatments in the 4-days treatment (Table 3) were also observed in the 30-day Tox List/Canonical Pathway analysis (Table 5) . Of the Tox Lists/Canonical Pathways that were common to both PB and conazole treatments at 30 days greater than 40% were metabolic. The pathways unique to PB treatment were almost all signaling pathways with little overlap between the two treatment times. Lists/Pathways common to Pro and Tri treatments mapped to the nuclear receptor pathways, LXR/RXR and TR/RXR activation, also observed at 4 days of treatment and not found in the groups of common or pathways unique to PB. Two signaling pathways were observed in these treatment groups; granulocyte macrophagecolony stimulating factor (GM-CSF) and glucocorticoid receptor signaling. The pathways/lists unique to Pro treatment were dominated by signaling pathways and showed major differences compared with those found at 4 days of treatment. There were five pathways/lists unique to Tri treatment. These were totally different from those found at 4 days ( Table 3) . As observed from the Tox Lists/Canonical Pathways analyses of the 4 days treatment data treatment, significant differences between PB and conazole treatments were observed while comparisons between the two conazoles indicated many common pathways.
Gene-Go MetaCore network analyses of groups of genes from Table 2 were conducted (see Supplemental Figures) . The first top network obtained from genes unique to PB treatment revealed The GO processes of mitosis and mitotic cell cycle, cell cycle phase and process, regulation of cell cycle interphase, M phase, and cell division. The first top network from genes altered by Pro treatment (excluding those common to three treatments) represented GO processes of amino acid metabolic processing, negative regulation of collagen binding, and negative regulation of collagen. The first top network from genes altered by Tri treatment (excluding those common to three treatments) represented GO processes of ribonucleoprotein complex biogenesis and assembly, translation and translational initiation, gene expression and RNA processing, and macromolecule biosynthetic and metabolic processing and complex assembly. The hubs from the top three GeneGo MetaCore networks using 30-days data are presented in Table  4 . These hubs from the control networks and the PB networks were different from those observed at 4 days of treatment and were generally comprised of transcription factors and genes associated with cell proliferation and apoptosis. The group of hubs from the Pro or Tri treatments both contained Hnf4a and Myc genes as found in the 4-days treatments.
Cell Cycle Genes (30 Days)
The significant DEGs after 30 days of treatment (i.e., PB 1268 genes, Pro 1410 genes, Tri 1081 genes) shown in Table 2 were mapped to cell cycle genes derived from the report of Whitfield et al. (2002) (Fig. 4) . Overall, the patterns of genes differ markedly among treatments across the cell cycle. There were two genes common to PB and both of the conazole treatments and eight genes common only to the two conazole treatments. Gene was overexpressed by each treatment. The patterns of the transcription factors and the number of genes associated with each transcription factor for PB, Pro and Tri treatments after 30 days of treatment (i.e., PB 1268 genes, Pro 1410 genes, Tri 1081 genes) are shown in Figure 5 . Each transcription factor listed passed statistical filters of LS and KS permutation p values of < 0.05. The expression changes associated with eight transcription factors were found to be common to all three treatments and these transcription factors had large numbers (106-200) of statistically significant (p < 0.05) DEGs associated with them (Fig. 5 ). There were also major differences in the specific transcription factors comparing PB and conazole treatments.
HCC Associated Genes Compared with Genes Altered by PB and Conazole Treatments (30 Days)
A catalog of genes was constructed from studies reported in the literature where molecular profiling and genomic analyses were used to identify genes associated with HCC. These genes were compared with lists of DEGs from Table 2 (i.e., PB 1268 genes, Pro 1410 genes, Tri 1081 genes) obtained from PB and conazole treatments using a 1.5-fold filter cutoff (Fig. 6) . Overall inspection of the patterns obtained from PB, Pro, and Tri treatments showed different patterns for each treatment. The genes that were common to PB and Pro or Tri treatments were Mt1 (metallothionein 1), Apcs (serum amyloid serum component), and Pck1 (phosphoenolpyruvate carboxylase 1 cytosolic). Genes common to both conazole treatments were Fst (follistatin), Actb (actin, beta), and Hsd3b2 (hydroxy-delta-5-steroid dehydrogenase, 3 beta-and steroid delta-isomerase 2). Genes from the HCC data set and the mouse liver data were also compared in terms of a common directionality (i.e., the same gene was similarly over-or underexpressed) in the human HCC data set and the chemical treatment data set. In the PB treatment data set, Pck1 was underexpressed and Apcs was overexpressed. These genes responded similarly in directionality in the HCC data set. The remaining three genes in the PB data set responded in opposite directions to those in the HCC data set. Pro treatment gave underexpression of C9 (complement component 9), Ass1 (argininosuccinate synthetase 1), Cxcl12 (chemokine [C-X-C motif] ligand 12 [stromal cellderived factor 1]), and overexpression of Pgd (phosphogluconate dehydrogenase), Fst, and Ubd (ubiquitin D). The directionality of gene expression responses of these genes in the HCC data set and Pro treatment data sets was the same. The remaining six genes responded in opposite directions in the HCC and Pro data sets. Tri treatment gave overexpression of Fst and Apcs genes and both were overexpressed in the HCC data set. The remaining five genes responded in opposite directions between the HCC and Tri data sets.
DISCUSSION
The goal of this study was to apply transcriptional analyses to probe more deeply into the similarities and differences between these apparently toxicologically similar agents. Here we applied a comprehensive set of tools to analyze the transcriptional responses of hepatic tissues from mice treated with PB, Pro, and Tri at tumorigenic exposure levels. These analyses have examined DEGs, subsets of DEGs (cell cycle genes, transcription factors, and HCC genes), and functions, pathways, and networks through the use of IPA Tox Lists, IPA Canonical Pathways, and Gene-Go MetaCore dynamic networks pathways and their central hubs. PB is a member of a class of barbiturates and is commonly used as a sedative and anti-epileptic drug. PB is a tumor promoter in the mouse and rat by facilitating the progression of hepatic preneoplastic foci (produced by genotoxic carcinogens) to adenomas and carcinomas. PB is a complete carcinogen as chronic administration of PB to several strains of mice induced both hepatocellular adenomas and carcinomas (IARC, 2001) . Pro, an environmental fungicide, is a hepatic tumor promoter in rats (Hakoi et al., 1992; INCHEM, 1987) and a hepatic complete carcinogen in mice producing both adenomas and carcinomas (INCHEM, 1987) . Tri is also an environmental fungicide and a hepatic complete carcinogen in mice, producing adenomas (INCHEM, 1981) . PB, Pro, and Tri are considered not to be directly genotoxic as these agents are generally negative in short term tests for genotoxicity (INCHEM, 1981 (INCHEM, , 1987 (INCHEM, , 1992 and PB has been found to be non-DNA reactive (Whysner et al., , 1998 . However, significant increases in mutant frequencies were observed in the livers of male C57BL/6 Big Blue mice fed Pro (2500 ppm) or Tri (1800 ppm) for 4 days (Ross et al., 2008) . In comparison, livers of Big Blue mice fed PB (2500 ppm) for 180 days failed to result in an increase in mutant frequency; however, significant differences in mutant spectra were observed in treated mice compared with controls (Shane et al., 2000) . Note. BMP, bone morphogenetic protein; IGF-1, IGF-insulin-like growth factor-1; IL-2, interleukin-2; JNK, c-Jun NH 2 -terminal kinase; LPS, lipopolysaccharide; NRF2, nuclear factor-erythroid 2-related factor 2; RAR, retinoic acid receptor; SAPK, stress-activated protein kinase; TGF-b, transforming growth factor-b. PB, Pro, and Tri induce several common toxicological effects in mice such as CYP enzyme induction (e.g., Cyp2b, Cyp3a proteins), increased hepatomegaly, and increased hepatic cell proliferation. However, conazoles and PB differ in their pharmacological properties. Conazoles strongly inhibit CYP51 and markedly decrease mouse serum cholesterol levels Peffer et al., 2007) , whereas PB produced no effect or a slight decrease of mouse serum cholesterol levels (Peffer et al., 2007) . Similarly, conazoles had greater effects on steroid biosynthesis than PB, particularly the transcription of cholesterogenic genes. We have determined from transcriptional analyses that Pro and Tri treatments produce profiles that have both overlapping and unique features. Moreover, many of the common features are not found in profiles from PB treatment. Pro and Tri are both triazole-containing conazoles that contain some chemical structural similarities (chloro (dichloro)phenyl and triazole moieties). The toxicological profiles of Pro and Tri although having many similarities also have differences. Although Pro can be metabolized, its metabolism is relatively slow compared with Tri, and its metabolism does not seem to be involved in its toxicity (Chen et al., 2008; INCHEM, 1987) . Tri is rapidly metabolized in the mouse to triadimenol which has similar toxicological properties in mice as the parent chemical (hepatotoxicity, hepatotumorigenesis, and serum cholesterol depletion) (INCHEM, 1987; Kenneke et al., 2008) . Therefore, the hepatic transcriptional profiles from mice treated with Tri are likely to be due to both Tri and triadimenol.
Transcriptional analyses have been used with success to discriminate between groups of toxicologically different agents usually to identify markers that can predict toxic outcomes. A number of studies have focused on rat hepatocarcinogenesis as a toxicity endpoint (Fielden et al., 2007; Kramer et al., 2004; Nie et al., 2006) . With respect to mouse hepatocarcinogenesis, microarray analysis was used to identify gene expression biomarkers in livers of mice treated with a series of chemicals (Thomas et al., 2007) , whereas Iida et al. (2005) found genes induced or repressed in unique patterns by specific carcinogens but not altered by noncarcinogens (Iida et al., 2005) . There is only one report that compares molecular changes induced by a conazole with those altered by PB. A 7-day dietary exposure to either PB or cyproconazole in mice significantly induced the overexpression of Gadd45b, whereas Mdm2 was slightly overexpressed by PB. (Peffer et al., 2007) . We found similar significant overexpression of Gadd45b induced by PB, Pro, and Tri treatments at both 4 and 30 days, whereas Mdm2 was not altered by any of these (data not shown). Gadd45b responds to stress, growth arrest conditions and treatment with DNA-damaging agents by mediating activation of the p38/JNK pathway. This activation is involved in the regulation of growth and apoptosis.
Increased cell proliferation is key step in chemical carcinogenesis. PB, Pro, and Tri increased cell proliferative responses to approximately similar extents, and these responses were similar in magnitude to that induced by other conazoles, fenbuconazole and cyproconazole (Juberg et al., 2006; Peffer et al., 2007) . However, many of the genes and canonical pathways underlying the proliferative processes altered by PB, Pro, and Tri treatment were different. Interestingly, there were a number of altered cell cycle genes common to Pro and Tri treatment, and this was observed at each treatment period. The labeling indices for PB and Pro were not significantly increased compared with control at 30 days, yet changes in cell cycle genes were evident. In fact, groups of the same cell cycle genes were altered by PB at both 4 and 30 days of treatment and similar effects were observed with Pro or Tri treatments. These results in toto suggest that hepatocytes in these treated mice might be proliferating at low rates that are undetectable by PCNA or Ki67 immunohistochemistry assays using labeling indices. 
79
PB has been shown to activate human CAR and Pro to activate human PXR using transactivation or transfection assays (Lemaire et al., 2006; Sueyoshi et al., 1999) . Based on our microarray transcriptional studies, nuclear receptor activation was induced by all three treatments. PB, Pro, and Tri treatments induced CAR/RXR, PXR/RXR, FXR/RXR, and PPAR-a/RXR activation. Furthermore, both conazoles also induced LXR/RXR and TR/RXR activation. Microarray analysis of hepatic gene expression profiles for prototypical ADME gene-inducing compounds in mice and rats in vivo has been reported (Slatter et al., 2006) . Consensus signatures were obtained for CAR and PXR ligands using clustering approaches. A series of genes were identified with CAR/PXR activation. These same genes were also identified in both published studies using prototype chemicals in wild type and CAR and PXR knockout mice (Maglich et al., 2002; Ueda et al., 2002) . Moreover, we identified these same genes as being altered by PB, Pro, and Tri treatments (data not shown). The conazole specific activation of LXR/RXR and TR/RXR could be related to the conazole's effects on cholesterol levels. LXR is an oxysterol (oxygenated derivatives of cholesterol) sensor and controls cholesterol levels. Thyroid hormone is associated with cholesterol lowering in the liver and is mediated by the TR receptor (Johansson et al., 2005) .
The analysis of the concordance of specific DEGs identified in HCC and those found in livers from Pro treatment can begin to identify potential common biomarkers between human and rodent species. A number of these DEGs need to considered further; in particular those where the over-or underexpression responses were concordant between the two species; ASS1, C9, CXCL12, PGD, FAT10, and FST. ASS1 is a key enzyme in the biosynthesis of arginine from citrulline in a two-step process involving the urea cycle enzymes ASS1 and argininosuccinate lyase. ASS1 catalyzes the conversion of citrulline and aspartic acid to argininosuccinate. HCC tumors that are sensitive to arginine depletion do not express mRNA levels of ASS1 (Cheng et al., 2007; Ensor et al., 2002) . C9 is the final component of the complement system. Although HepG2 cells (human hepatoma-derived cell line) synthesized and secreted a series of functional complement proteins (C1-C5), these cells did not produce detectable quantities of C9 protein (Morris et al., 1982) . A highly effective molecular index containing 13 genes (e.g., CXCL12) was developed for the diagnosis of HCC based on expression profiles of normal, cirrhotic and HCC tissues (Paradis et al., 2003) . CXCL12 is a member of a family of intercrines which activate leukocytes and are often induced by proinflammatory stimuli. PGD is the second dehydrogenase in the pentose phosphate shunt, a process that generates nicotinamide adenine dinucleotide phosphate, reduced for reductive biosynthesis reactions within cells. Based on our microarray analyses each of the four genes (ASS1, C9, CXCL2, PGD) were underexpressed in both HCC and in the livers from mice treated with Pro. FAT10 (UBD) has been reported to be highly overexpressed in 90% of patients with HCC (Lee et al., 2003) . FAT10 is associated with a variety of cellular processes including cell cycle progression, DNA repair and apoptosis (Jentsch and Pyrowolakis, 2000) . FST is an activin antagonist. Activins are members of the TGFb superfamily of growth and differentiation factors. In HCC, and also in animal models, FST expression was increased in about 60% of tumor tissues examined. Increased FST protein levels were also found in the blood of patients with liver cirrhosis and HCC (Deli et al., 2008) . Both Fat10 and FST were overexpressed in both HCC and in the livers from mice treated with Pro. We view these genes as potential biomarkers for human relevance evaluations.
In conclusion, the transcriptional profiles of these three agents revealed overlaps in responses; however, there were also many differences in transcriptional features. These differences resided in the expression of specific cell cycle genes, nuclear receptors, signaling pathways, transcription factors, gene networks, and their central hubs, and genes associated with HCC. There were genes and pathways that were similar between the two conazoles and not affected by PB treatment. These conclusions are best exemplified in Figure 7 , a principal component analysis analyses of DEGs from each array from PB, Pro, and Tri treatments at 30 days, which shows a significant separation of both conazoles from PB and a closer relationship between the two conazoles.
Based on our analyses we conclude that, whereas all three agents induce mouse hepatocarcinogenesis, the chemically induced alterations of the molecular processes that are involved in the transition of normal hepatocytes to neoplasia are inherently different between these conazoles and PB. Therefore, the mechanisms or MOA of these conazoles are proposed to be unlike PB and their tumorigenic effects are potentially relevant to informing human health assessment. We are currently extending these transcriptomic comparisons to the FIG. 7 . Principal component analysis of DEGs from PB, Pro, and Tri treatments at 30 days. The gene list of 2629 genes for the principal component analysis was generated by combining the DEGs from PB, Pro, and Tri treatments and removing duplicates. The value for each gene within each sample was computed as the ratio of the expression level for the sample to the average of control expression levels for that gene.
FIG. 6.
Heatmap of DEGs from PB and conazole treatments (30-days treatments with a 1.5-fold filter) compared with genes known to be associated with HCC. The red color denotes overexpression while the green color denotes underexpression. The colors on the PB and conazole heatmap are scaled to fold changes. The HCC heatmap represents genes as either overexpressed (dark red) or underexpressed (dark green) without scaling the color for fold levels. The HCC results for HGFAC were mixed and are not represented. 
